Journal article

Zuclopenthixol versus placebo for schizophrenia

Michael Lacey, Mahesh B Jayaram



BACKGROUND: Zuclopenthixol is an older antipsychotic that has three distinct formulations (zuclopenthixol dihydrochloride, zuclopenthixol acetate or Acuphase and zuclopenthixol decanoate). Although it has been in common use for many years no previous systematic review of its efficacy compared to placebo in schizophrenia has been undertaken. OBJECTIVES: To evaluate the effectiveness of all formulations of zuclopenthixol when compared with a placebo in schizophrenia. SEARCH METHODS: On 6 November 2013 and 20 October 2015, we searched the Cochrane Schizophrenia Group Trials Register, which is based on regular searches of MEDLINE, EMBASE, CINAHL, BIOSIS, AMED, PubMed, PsycINFO, and registries of..

View full abstract

University of Melbourne Researchers


Awarded by Cochrane Collaboration Programme Grant, UK

Awarded by National Institute for Health Research

Funding Acknowledgements

Internal sourcesLeeds and York Partnerships NHS Foundation Trust, UK.Both authors were employed by this organisation at the time of writing this reviewExternal sourcesUniversity of Leeds, UK.ML is undertaking a masters degree with this organisation and has access to their resources. An adapted version of this review will be submitted as ML's masters dissertationCochrane Collaboration Programme Grant 2011, Reference number: 10/4001/15, UK.